Immunopotentiating of mucosal and systemic antibody responses in mice by intranasal immunization with HLT-combined influenza virosomal vaccine

Vaccine

Volumn 18, Issue 25, 2000, Pages 2838-2842

  Cusi, M G ^a   Lomagistro, M M ^a   Valassina, M ^a   Valensin, P E ^a   Gluck R ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b Berna Biotech AG   (Switzerland)

Author keywords

Heat labile toxin; Influenza virosome; Procholeragenoid

Indexed keywords

INFLUENZA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPOTENTIATION; LUNG FUNCTION; MEDIATOR RELEASE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REINFECTION; RESPIRATORY TRACT MUCOSA; VACCINATION;

EID: 0034660349     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00072-4     Document Type: Article

References (22)

1. Glezan W.P. Serious morbidity and mortality associated with influenza epidemics. Epidemiol. Rev. 4:1993;25-44.
2. Immunizations practices Advisory Committee. Prevention and control of influenza. Morbid. Mortal. Wkly. Rep. 45:1996;1-24.
3. Couch R.B., Kasel J.A., Glezen W.P., Cate T.R., Six H.R., Taber L.H., Frank A.L., Greenberg S.B., Zahradnik J.M., Keital W.A. Influenza: its control in persons and populations. J. Infect. Dis. 153:1986;431-440.
4. Renegar K.B. Influenza virus infections and immunity: a review of human and animal models. Lab. Animal Sci. 42:1992;222-232.
5. Ada G.L., Jones P.D. The immune response to influenza infection. Curr. Topics Microbiol. Immunol. 128:1986;3-54.
6. Tamura S.-I., Ito Y., Asanuma H., Hirabayashi Y., Suzuki Y., Nagamine T., Aizawa C., Kurata T. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J. Immunol. 149:1992;981-988.
7. Tamura S.-I., Funato H., Hirabayashi Y., Kikuta K., Suzuki Y., Nagamine T., Aizawa C., Nakagawa M., Kurata T. Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza. Vaccine. 8:1990;479-485.
8. Renegar K.B., Small P.A. Jr. Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. J. Virol. 65:1991;2146-2148.
9. Johnson P.R. Jr, Feldman S., Thompson J.M., Mahoney J.D., Wright P.F. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J. Med. Virol. 17:1985;325-335.
10. Wright P.F., Murphy B.R., Kervina M., Lawrence E.M., Phelan M.A., Karson D.T. Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory. Infect. Immun. 40:1983;1092-1095.
11. Gruber W.C., Hinson H.P., Holland K.L., Thompson J.M., Reed G.W., Wright P.F. Comparative trial of large-particle aerosol and nose drop administration of live attenuated influenza vaccines. J. Infect. Dis. 168:1993;1282-1285.
12. Harden K., McG Harden R. Response of patients offered influenza vaccination by injection and nasal insufflation. BMJ. 1:1977;686.
13. Snider D.P. The mucosal activities of ADP-ribosylating bacterial enterotoxins. Crit. Rev. Immunol. 15:1995;317-348.
14. Pierce N.F., Cray W., Sacci J.B. Jr, Craig J.P., René Germanier R., Furer E. Procholeragenoid: a safe and effective antigen for oral immunization against experimental cholera. Infect. Immun. 40:1983;1112-1118.
15. Eyles J.E., Williamson E.D., Alpar H.O. Immunological responses to nasal delivery of free and microencapsulated tetenus toxoid: studies on the effect of vehicle volume. Int. J. Pharm. 189:1999;75-79.
16. Glück R., Mischler R., Finkel B., Que J.U., Scarpa S., Cryz S.J. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet. 344:1994;160-163.
17. Takao S.I., Kiyotani K., Sakaguchi T., Fujii Y., Seno M., Yoshida T. Protection of mice from respiratory Sendai virus infections by recombinant vaccine viruses. J. Virol. 71:1977;832-838.
18. Heirholzed J.C., Suggs M.T. Standardized viral hemagglutination and hemagglutination inhibition tests. Applied Microbiology. 18:1969;816.
19. Tomoda T., Morita H., Kurashige T., Maassab H.F. Prevention of influenza by intranasal administration of cold-recombinant, live-attenuated influenza vaccine: importance of interferon-gamma production and local IgA response. Vaccine. 13:1995;185-190.
20. Bot A., Bot S., Bona C.A. Protective role of gamma interferon during recall response to influenza virus. J. Virol. 72:1998;6637-6645.
21. Tamura S., Miyata K., Matsuo K., Asanuma H., Takahashi H., Nakajima K., Suzuki Y., Aizawa C., Kurata T. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J. Immunol. 156:1996;3892.
22. Walker R., Clements J.D. Use of heat-labile toxin of enterotoxigenic Escherichia coli to facilitate mucosal immunization. Vaccine Res. 2:1993;1-9.